CN101374415A - 用于治疗代谢紊乱的化合物 - Google Patents

用于治疗代谢紊乱的化合物 Download PDF

Info

Publication number
CN101374415A
CN101374415A CNA2007800035511A CN200780003551A CN101374415A CN 101374415 A CN101374415 A CN 101374415A CN A2007800035511 A CNA2007800035511 A CN A2007800035511A CN 200780003551 A CN200780003551 A CN 200780003551A CN 101374415 A CN101374415 A CN 101374415A
Authority
CN
China
Prior art keywords
carbon atoms
formula
compound
hydrogen
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800035511A
Other languages
English (en)
Chinese (zh)
Inventor
沙林·夏尔马
里德·W·冯博斯特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of CN101374415A publication Critical patent/CN101374415A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800035511A 2006-01-25 2007-01-22 用于治疗代谢紊乱的化合物 Pending CN101374415A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76206806P 2006-01-25 2006-01-25
US60/762,068 2006-01-25

Publications (1)

Publication Number Publication Date
CN101374415A true CN101374415A (zh) 2009-02-25

Family

ID=38309906

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800035511A Pending CN101374415A (zh) 2006-01-25 2007-01-22 用于治疗代谢紊乱的化合物

Country Status (11)

Country Link
US (1) US7947735B2 (https=)
EP (1) EP1976378A4 (https=)
JP (1) JP2009528275A (https=)
KR (1) KR20080086523A (https=)
CN (1) CN101374415A (https=)
AU (1) AU2007208127A1 (https=)
CA (1) CA2636290A1 (https=)
IL (1) IL192852A (https=)
NZ (1) NZ569729A (https=)
WO (1) WO2007087506A2 (https=)
ZA (1) ZA200805645B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008600A (es) * 2003-02-13 2005-11-04 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CN1774244A (zh) * 2003-04-15 2006-05-17 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
MXPA05011592A (es) * 2003-04-30 2005-12-15 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080106455A (ko) * 2006-03-31 2008-12-05 웰스태트 테러퓨틱스 코포레이션 대사장애의 조합치료
US7935689B2 (en) * 2006-05-18 2011-05-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP5252585B2 (ja) * 2006-06-09 2013-07-31 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
WO2008022267A2 (en) * 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
DE102007058842A1 (de) * 2007-12-05 2009-06-10 Grünenthal GmbH Arzneimittel
JP5496913B2 (ja) * 2008-01-15 2014-05-21 ウェルスタット セラピューティクス コーポレイション 代謝異常の治療のための化合物
JP5339545B2 (ja) 2008-03-13 2013-11-13 ウェルスタット セラピューティクス コーポレイション 尿酸を減少させる化合物及び方法
WO2012033720A1 (en) 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5035M (https=) 1964-07-28 1967-05-02
US4080335A (en) * 1975-07-28 1978-03-21 Beecham Group Limited Anorexic chromans
FR2653119B1 (fr) 1989-10-18 1994-08-05 Lipha Nouveaux aryloxy alcoyl benzenes, leurs procedes de preparation et les compositions pharmaceutiques en renfermant.
MXPA03011558A (es) 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CA2502297C (en) 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MXPA05008600A (es) 2003-02-13 2005-11-04 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CN1774244A (zh) 2003-04-15 2006-05-17 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
CN1777576A (zh) 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
MXPA05011592A (es) 2003-04-30 2005-12-15 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
DE602004031954D1 (de) 2003-08-20 2011-05-05 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
CA2547430A1 (en) * 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited Receptor function regulating agent

Also Published As

Publication number Publication date
EP1976378A4 (en) 2010-06-09
KR20080086523A (ko) 2008-09-25
IL192852A0 (en) 2009-02-11
WO2007087506A3 (en) 2007-11-22
EP1976378A2 (en) 2008-10-08
CA2636290A1 (en) 2007-08-02
WO2007087506A2 (en) 2007-08-02
US20080306150A1 (en) 2008-12-11
US7947735B2 (en) 2011-05-24
IL192852A (en) 2012-03-29
NZ569729A (en) 2011-07-29
AU2007208127A1 (en) 2007-08-02
ZA200805645B (en) 2009-09-30
JP2009528275A (ja) 2009-08-06

Similar Documents

Publication Publication Date Title
EP1988772B1 (en) Compounds for the treatment of metabolic disorders
US7820721B2 (en) Compounds for the treatment of metabolic disorders
US7935689B2 (en) Compounds for the treatment of metabolic disorders
CN101374415A (zh) 用于治疗代谢紊乱的化合物
US20090156681A1 (en) Compounds for the treatment of metabolic disorders
US7915429B2 (en) Compounds for the treatment of metabolic disorders
US20110166233A1 (en) Compounds for the treatment of metabolic disorders
MX2008009594A (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090225